HK1133398A1 - Liposome formulation of mitoxantrone and method for preparation thereof - Google Patents

Liposome formulation of mitoxantrone and method for preparation thereof

Info

Publication number
HK1133398A1
HK1133398A1 HK10100560.8A HK10100560A HK1133398A1 HK 1133398 A1 HK1133398 A1 HK 1133398A1 HK 10100560 A HK10100560 A HK 10100560A HK 1133398 A1 HK1133398 A1 HK 1133398A1
Authority
HK
Hong Kong
Prior art keywords
mitoxantrone
preparation
liposome formulation
liposome
formulation
Prior art date
Application number
HK10100560.8A
Inventor
Chunlei Li
Jinxu Wang
Caixia Wang
Yanhui Li
Dongmin Shen
Wenmin Guo
Li Zhang
Lan Zhang
Original Assignee
Cspc Zhongqi Pharmaceutical Technology Shijiazhua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Technology Shijiazhua filed Critical Cspc Zhongqi Pharmaceutical Technology Shijiazhua
Publication of HK1133398A1 publication Critical patent/HK1133398A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
HK10100560.8A 2006-12-29 2010-01-20 Liposome formulation of mitoxantrone and method for preparation thereof HK1133398A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101023398A CN101209243B (en) 2006-12-29 2006-12-29 Liposome medicament and preparation thereof
PCT/CN2007/071403 WO2008080367A1 (en) 2006-12-29 2007-12-29 Liposome formulation and process for preparation thereof

Publications (1)

Publication Number Publication Date
HK1133398A1 true HK1133398A1 (en) 2010-03-26

Family

ID=39588170

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10100560.8A HK1133398A1 (en) 2006-12-29 2010-01-20 Liposome formulation of mitoxantrone and method for preparation thereof

Country Status (16)

Country Link
US (2) US20110002977A1 (en)
EP (1) EP2123260B1 (en)
JP (3) JP2010514708A (en)
KR (1) KR101126629B1 (en)
CN (1) CN101209243B (en)
AU (1) AU2007341803B2 (en)
BR (1) BRPI0720733A2 (en)
CA (1) CA2673924C (en)
CO (1) CO6190601A2 (en)
CU (1) CU23980B1 (en)
ES (1) ES2401526T3 (en)
HK (1) HK1133398A1 (en)
MX (1) MX2009007089A (en)
MY (1) MY150670A (en)
RU (1) RU2494729C2 (en)
WO (1) WO2008080367A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (en) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
JPWO2010058840A1 (en) * 2008-11-20 2012-04-19 テルモ株式会社 Drug release means from liposome and evaluation method for release
AU2014200717B2 (en) * 2009-03-30 2016-02-25 Eisai R&D Management Co., Ltd. Liposome composition
SI2415470T1 (en) * 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposome composition
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
CN101897667B (en) * 2009-05-26 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 Doxorubicin hydrochloride liposome injection and preparation technology thereof
ES2732149T3 (en) * 2009-07-14 2019-11-20 Polypid Ltd Composition of sustained release drug vehicles
CN102038640B (en) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament containing cholesterol PEG modifier and preparation method thereof
BR112012028787A2 (en) * 2010-05-10 2017-03-14 J Miller Joseph therapeutic liposomes and methods for producing and using the same
CN101912363A (en) * 2010-07-29 2010-12-15 蔡海德 Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine
US20150283272A1 (en) * 2010-10-27 2015-10-08 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
EP3915545A1 (en) * 2011-10-25 2021-12-01 The University of British Columbia Limit size lipid nanoparticles and related methods
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
MX2015005992A (en) * 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Improved method for the preparation of liposome encapsulated vincristine for therapeutic use.
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP6605446B2 (en) 2013-03-15 2019-11-13 ザ ユニバーシティ オブ ブリティッシュ コロンビア Lipid nanoparticles and related methods for transfection
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
KR101503492B1 (en) * 2013-07-03 2015-03-19 전북대학교산학협력단 Liposomes capsule containing lipid and lysosomal enzymes, and manufacturing method thereof
HUE052968T2 (en) 2014-04-30 2021-05-28 Fujifilm Corp Liposome composition and production method therefor
JP6263609B2 (en) * 2014-04-30 2018-01-17 富士フイルム株式会社 Liposome composition and production method thereof
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
PL3372232T3 (en) 2015-11-02 2021-09-27 Fujifilm Corporation Tumor therapeutic agent comprising gemcitabine liposome composition and kit
RU2765736C2 (en) * 2017-01-18 2022-02-02 Темасек Лайф Сайенсиз Лаборатори Лимитед Hyper-stabilized liposomes increasing directed targeting of mitotic cells
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
WO2018204495A1 (en) * 2017-05-02 2018-11-08 Synthetic Genomics, Inc. Nanolipoprotein particles and related compositions methods and systems for loading rna
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
RU2728976C2 (en) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Liposomal composition and preparation thereof
CN108721644B (en) * 2018-06-05 2021-06-08 常州金远药业制造有限公司 Preparation method of taxane medicine liposome
CN110711178A (en) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 Application of mitoxantrone hydrochloride liposome in treating non-Hodgkin lymphoma
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3167470A1 (en) * 2020-02-10 2021-08-19 Chunlei Li Use of mitoxantrone hydrochloride liposome for treating breast cancer
CN115279344A (en) * 2020-03-12 2022-11-01 石药集团中奇制药技术（石家庄）有限公司 Application of mitoxantrone hydrochloride liposome
CN115427020A (en) * 2020-04-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 Application of mitoxantrone hydrochloride liposome
CN113876711A (en) * 2020-07-01 2022-01-04 江苏长泰药业有限公司 Preparation process of doxorubicin hydrochloride liposome
JP2023537049A (en) 2020-08-07 2023-08-30 石薬集団中奇制薬技術（石家庄）有限公司 Use of mitoxantrone hydrochloride liposomes and pegasparagase
CN115955971A (en) * 2020-08-27 2023-04-11 石药集团中奇制药技术（石家庄）有限公司 Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone
CN116600788A (en) * 2020-12-15 2023-08-15 石药集团中奇制药技术（石家庄）有限公司 Application of mitoxantrone hydrochloride liposome
JP2024513965A (en) 2021-04-16 2024-03-27 石薬集団中奇制薬技術（石家庄）有限公司 Application of Mitoxantrone Hydrochloride Liposome
EP4349325A1 (en) 2021-05-28 2024-04-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumors
CN115770288A (en) * 2021-09-07 2023-03-10 石药集团中奇制药技术（石家庄）有限公司 Use of mitoxantrone liposomes, bortezomib and dexamethasone for treating multiple myeloma
WO2023207931A1 (en) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 Use of mitoxantrone liposome in combination with anti-angiogenic targeted drug for treating ovarian cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5169635A (en) * 1989-11-17 1992-12-08 Fuji Photo Film Co., Ltd. Photoresponsive liposome
CA2186745A1 (en) * 1994-03-28 1995-10-05 Hiroshi Kikuchi Liposome with increased retention volume
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
WO1996032930A1 (en) * 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
KR100711315B1 (en) * 1997-09-16 2007-04-27 오에스아이 파마슈티컬스, 인코포레이티드 Liposomal camptothecin formulations
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6355268B1 (en) * 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
EP1196144B1 (en) * 1999-07-16 2004-09-22 Alza Corporation A liposome composition having resistance to freeze/thaw damage
ES2186484B1 (en) * 2000-10-10 2004-07-01 Lipotec, S.A. LIPOSOMES ENCAPSULATING ANTI-CANCER DRUGS AND USE OF THEM IN THE TREATMENT OF EVIL TUMORS.
CN1469735A (en) * 2000-10-16 2004-01-21 ����˹��ҩ�﹫˾ Liposomal formulation of mitoxantrone
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein-stabilized liposomal formulations of pharmaceutical agents
AU2003293140A1 (en) * 2002-11-26 2004-06-18 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US7288396B2 (en) * 2003-09-11 2007-10-30 Kosan Biosciences Incorporated Biosynthetic gene cluster for leptomycins
RU2258530C1 (en) * 2004-04-27 2005-08-20 Генкин Дмитрий Дмитриевич Method for preventing and correcting cutaneous alterations
DK1746976T3 (en) * 2004-05-03 2017-04-10 Merrimack Pharmaceuticals Inc LIPOSOMES SUITABLE FOR PHARMACEUTICAL SUPPLY
CN101001633A (en) * 2004-05-21 2007-07-18 特兰萨夫公司 Treatment of lung diseases and pre-lung disease conditions
CN1242740C (en) * 2004-08-05 2006-02-22 常州太平洋药物研究所有限公司 Mitoxantrone or mitoxantrone hydrochloride liposome injection and its preparing process
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
JP2006298844A (en) * 2005-04-21 2006-11-02 Konica Minolta Medical & Graphic Inc Liposome-containing preparation given by including pharmaceutical compound in liposome
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
US8226975B2 (en) * 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US7703945B2 (en) 2006-06-27 2010-04-27 Cree, Inc. Efficient emitting LED package and method for efficiently emitting light
CN101209243B (en) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
SI2415470T1 (en) * 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposome composition
JP5480867B2 (en) * 2011-10-07 2014-04-23 住友ゴム工業株式会社 Pneumatic tire

Also Published As

Publication number Publication date
CN101209243B (en) 2010-12-08
CA2673924A1 (en) 2008-07-10
AU2007341803A2 (en) 2009-09-03
KR101126629B1 (en) 2012-03-26
KR20090094043A (en) 2009-09-02
CU20090114A7 (en) 2011-02-24
CA2673924C (en) 2013-10-01
ES2401526T3 (en) 2013-04-22
BRPI0720733A2 (en) 2014-01-07
CN101209243A (en) 2008-07-02
JP2010514708A (en) 2010-05-06
CO6190601A2 (en) 2010-08-19
US20110002977A1 (en) 2011-01-06
AU2007341803A1 (en) 2008-07-10
WO2008080367A1 (en) 2008-07-10
MY150670A (en) 2014-02-28
EP2123260B1 (en) 2013-02-20
JP2013177397A (en) 2013-09-09
RU2494729C2 (en) 2013-10-10
EP2123260A4 (en) 2010-03-17
MX2009007089A (en) 2009-10-08
US10028913B2 (en) 2018-07-24
JP2015180652A (en) 2015-10-15
RU2009126983A (en) 2011-02-10
AU2007341803B2 (en) 2011-08-11
JP6187961B2 (en) 2017-08-30
US20160235671A1 (en) 2016-08-18
CU23980B1 (en) 2014-01-29
EP2123260A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
HK1133398A1 (en) Liposome formulation of mitoxantrone and method for preparation thereof
IL262205A (en) Protein formulations and methods of making same
GB2455041B (en) Collagen preparation and method of isolation
EP2076558B8 (en) Composition comprising neopentasilane and method of preparing same
HK1160385A1 (en) Composition and method for preparing stable unilamellar liposomal suspension
ZA200900345B (en) Preparation of pharmaceutical formulations
EP2331072B8 (en) Methods and compositions for oral administration of proteins
ZA201203316B (en) Liposome of irinotecan or its hydrochloride and preparation method thereof
EP2021455A4 (en) Cytoblock preparation system and methods of use
EP2405758A4 (en) Methods and compositions for liposomal formulation of antigens and uses thereof
IL225961A (en) Liposomal nanoparticles and method of preparation thereof
EP2152293A4 (en) Compositions for protein delivery and methods of use thereof
EP2080510A4 (en) Method for production of liposome preparation
EP1938842A4 (en) Method for preparation of pharmaceutical composition having improved disintegradability
PL1993557T3 (en) Novel epoprostenol formulation and method of making thereof
ZA200909147B (en) IM-16 crystallized solid and method of preparation thereof
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
EP1964538A4 (en) Preparation method of pharmaceutials
IL192564A0 (en) Composition and method of use thereof
IL191922A0 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
ZA201101214B (en) Formulations of canfosfamide and their preparation
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
GB0622341D0 (en) Novel compounds and methods for their preparation
IL190726A0 (en) Dnt-benzenesulfonate and methods of preparation thereof
IL192553A0 (en) Dnt-fumarate and methods of preparation thereof